nodes	percent_of_prediction	percent_of_DWPC	metapath
Riluzole—CYP1A1—Dacarbazine—pancreatic cancer	0.0877	0.124	CbGbCtD
Riluzole—ABCG2—Tamoxifen—pancreatic cancer	0.0756	0.107	CbGbCtD
Riluzole—CYP1A1—Tamoxifen—pancreatic cancer	0.0698	0.0987	CbGbCtD
Riluzole—ABCG2—Erlotinib—pancreatic cancer	0.0643	0.0909	CbGbCtD
Riluzole—CYP1A1—Erlotinib—pancreatic cancer	0.0593	0.0839	CbGbCtD
Riluzole—ABCG2—Irinotecan—pancreatic cancer	0.058	0.0821	CbGbCtD
Riluzole—ABCG2—Fluorouracil—pancreatic cancer	0.0557	0.0788	CbGbCtD
Riluzole—ABCG2—Docetaxel—pancreatic cancer	0.0425	0.0602	CbGbCtD
Riluzole—ABCG2—Sunitinib—pancreatic cancer	0.0423	0.0599	CbGbCtD
Riluzole—CYP1A2—Dacarbazine—pancreatic cancer	0.0392	0.0554	CbGbCtD
Riluzole—ABCG2—Doxorubicin—pancreatic cancer	0.0317	0.0449	CbGbCtD
Riluzole—CYP1A2—Tamoxifen—pancreatic cancer	0.0312	0.0441	CbGbCtD
Riluzole—CYP1A2—Erlotinib—pancreatic cancer	0.0265	0.0375	CbGbCtD
Riluzole—CYP1A2—Fluorouracil—pancreatic cancer	0.023	0.0325	CbGbCtD
Riluzole—SLC7A11—Transcriptional activation by NRF2—NFE2L2—pancreatic cancer	0.0027	0.102	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—FGF13—pancreatic cancer	0.00156	0.0588	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—SLC29A1—pancreatic cancer	0.00128	0.0485	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—SLC29A1—pancreatic cancer	0.00068	0.0257	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TYMP—pancreatic cancer	0.000645	0.0244	CbGpPWpGaD
Riluzole—SLC7A11—Transcriptional activation by NRF2—PIK3CA—pancreatic cancer	0.000518	0.0196	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—DPYD—pancreatic cancer	0.000511	0.0193	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—NRP1—pancreatic cancer	0.000437	0.0165	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—NFE2L2—pancreatic cancer	0.000437	0.0165	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—CD44—pancreatic cancer	0.000431	0.0163	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000424	0.016	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—TGFA—pancreatic cancer	0.000416	0.0157	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—SLC2A2—pancreatic cancer	0.000408	0.0154	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—NDRG1—pancreatic cancer	0.000394	0.0149	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—NFE2L2—pancreatic cancer	0.00038	0.0143	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—SSTR1—pancreatic cancer	0.000348	0.0132	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000346	0.0131	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—SSTR2—pancreatic cancer	0.000335	0.0127	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—HSPA1A—pancreatic cancer	0.000313	0.0118	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TYMS—pancreatic cancer	0.000291	0.011	CbGpPWpGaD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—GADD45A—pancreatic cancer	0.000288	0.0109	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—AHR—pancreatic cancer	0.000277	0.0105	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—AHR—pancreatic cancer	0.000277	0.0105	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—NFE2L2—pancreatic cancer	0.00027	0.0102	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—pancreatic cancer	0.00027	0.0102	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—FOXM1—pancreatic cancer	0.000264	0.00997	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—KDR—pancreatic cancer	0.00026	0.00982	CbGpPWpGaD
Riluzole—SLC7A11—SLC-mediated transmembrane transport—SLC2A2—pancreatic cancer	0.000257	0.00971	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—NOTCH1—pancreatic cancer	0.000245	0.00925	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—KDR—pancreatic cancer	0.000227	0.00856	CbGpPWpGaD
Riluzole—CYP1A1—Oxidative Stress—SOD2—pancreatic cancer	0.000211	0.00798	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IFNA5—pancreatic cancer	0.000206	0.0078	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—PPP2R5B—pancreatic cancer	0.000195	0.00737	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—SST—pancreatic cancer	0.000191	0.00721	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—PIK3CB—pancreatic cancer	0.000188	0.0071	CbGpPWpGaD
Riluzole—CYP1A1—Estrogen Receptor Pathway—STAT3—pancreatic cancer	0.000181	0.00682	CbGpPWpGaD
Riluzole—CYP1A1—Melatonin metabolism and effects—APOE—pancreatic cancer	0.000178	0.00672	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—AHR—pancreatic cancer	0.000176	0.00667	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—AHR—pancreatic cancer	0.000176	0.00667	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NFE2L2—pancreatic cancer	0.000172	0.0065	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—NFE2L2—pancreatic cancer	0.000172	0.0065	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—SMAD4—pancreatic cancer	0.00017	0.00644	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—NRP1—pancreatic cancer	0.000165	0.00623	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—ACVR1B—pancreatic cancer	0.00016	0.00603	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NR5A2—pancreatic cancer	0.00016	0.00603	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—FXYD3—pancreatic cancer	0.000154	0.0058	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—SRC—pancreatic cancer	0.000151	0.00569	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.00015	0.00568	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—TERT—pancreatic cancer	0.000146	0.00551	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—NRAS—pancreatic cancer	0.000145	0.00547	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—PDX1—pancreatic cancer	0.000144	0.00546	CbGpPWpGaD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—HIF1A—pancreatic cancer	0.000139	0.00527	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—HES1—pancreatic cancer	0.000137	0.00517	CbGpPWpGaD
Riluzole—SCN5A—Cardiac Progenitor Differentiation—TGFB1—pancreatic cancer	0.000131	0.00497	CbGpPWpGaD
Riluzole—SLC7A11—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	0.000131	0.00493	CbGpPWpGaD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC29A1—pancreatic cancer	0.000125	0.00473	CbGpPWpGaD
Riluzole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—pancreatic cancer	0.000125	0.00472	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—KRAS—pancreatic cancer	0.000125	0.00471	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NRP1—pancreatic cancer	0.000118	0.00445	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—CD44—pancreatic cancer	0.000117	0.00441	CbGpPWpGaD
Riluzole—CYP1A2—Estrogen Receptor Pathway—STAT3—pancreatic cancer	0.000115	0.00435	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—HIF1A—pancreatic cancer	0.000115	0.00433	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—PIK3CA—pancreatic cancer	0.000114	0.00433	CbGpPWpGaD
Riluzole—CYP1A2—Melatonin metabolism and effects—APOE—pancreatic cancer	0.000113	0.00428	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IFNA1—pancreatic cancer	0.000113	0.00427	CbGpPWpGaD
Riluzole—SLC7A11—Cell surface interactions at the vascular wall—HRAS—pancreatic cancer	0.000106	0.004	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—IFNA2—pancreatic cancer	0.000105	0.00398	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	0.000102	0.00387	CbGpPWpGaD
Riluzole—SLC7A11—NRF2 pathway—TGFB1—pancreatic cancer	9.86e-05	0.00373	CbGpPWpGaD
Riluzole—ABCG2—Fluoropyrimidine Activity—TP53—pancreatic cancer	9.66e-05	0.00365	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	9.58e-05	0.00362	CbGpPWpGaD
Riluzole—SCN5A—L1CAM interactions—SRC—pancreatic cancer	9.14e-05	0.00345	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—SLC2A2—pancreatic cancer	9.11e-05	0.00344	CbGpPWpGaD
Riluzole—Asthenia—Gemcitabine—pancreatic cancer	8.94e-05	0.000335	CcSEcCtD
Riluzole—Haematuria—Epirubicin—pancreatic cancer	8.92e-05	0.000334	CcSEcCtD
Riluzole—Confusional state—Docetaxel—pancreatic cancer	8.92e-05	0.000334	CcSEcCtD
Riluzole—Photosensitivity reaction—Doxorubicin—pancreatic cancer	8.86e-05	0.000332	CcSEcCtD
Riluzole—Hepatobiliary disease—Epirubicin—pancreatic cancer	8.84e-05	0.000332	CcSEcCtD
Riluzole—Anaphylactic shock—Docetaxel—pancreatic cancer	8.84e-05	0.000332	CcSEcCtD
Riluzole—Oedema—Docetaxel—pancreatic cancer	8.84e-05	0.000332	CcSEcCtD
Riluzole—Weight increased—Doxorubicin—pancreatic cancer	8.83e-05	0.000331	CcSEcCtD
Riluzole—Epistaxis—Epirubicin—pancreatic cancer	8.82e-05	0.000331	CcSEcCtD
Riluzole—Pruritus—Gemcitabine—pancreatic cancer	8.82e-05	0.000331	CcSEcCtD
Riluzole—Infection—Docetaxel—pancreatic cancer	8.78e-05	0.000329	CcSEcCtD
Riluzole—Weight decreased—Doxorubicin—pancreatic cancer	8.78e-05	0.000329	CcSEcCtD
Riluzole—Sinusitis—Epirubicin—pancreatic cancer	8.77e-05	0.000329	CcSEcCtD
Riluzole—Diarrhoea—Irinotecan—pancreatic cancer	8.75e-05	0.000328	CcSEcCtD
Riluzole—Agranulocytosis—Epirubicin—pancreatic cancer	8.73e-05	0.000327	CcSEcCtD
Riluzole—Pneumonia—Doxorubicin—pancreatic cancer	8.7e-05	0.000326	CcSEcCtD
Riluzole—Shock—Docetaxel—pancreatic cancer	8.7e-05	0.000326	CcSEcCtD
Riluzole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—pancreatic cancer	8.7e-05	0.00329	CbGpPWpGaD
Riluzole—Nervous system disorder—Docetaxel—pancreatic cancer	8.67e-05	0.000325	CcSEcCtD
Riluzole—Pruritus—Fluorouracil—pancreatic cancer	8.67e-05	0.000325	CcSEcCtD
Riluzole—Thrombocytopenia—Docetaxel—pancreatic cancer	8.66e-05	0.000325	CcSEcCtD
Riluzole—Infestation—Doxorubicin—pancreatic cancer	8.65e-05	0.000325	CcSEcCtD
Riluzole—Infestation NOS—Doxorubicin—pancreatic cancer	8.65e-05	0.000325	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—IAPP—pancreatic cancer	8.64e-05	0.00327	CbGpPWpGaD
Riluzole—Tachycardia—Docetaxel—pancreatic cancer	8.63e-05	0.000324	CcSEcCtD
Riluzole—Skin disorder—Docetaxel—pancreatic cancer	8.59e-05	0.000322	CcSEcCtD
Riluzole—ABCG2—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—pancreatic cancer	8.57e-05	0.00324	CbGpPWpGaD
Riluzole—Bradycardia—Epirubicin—pancreatic cancer	8.55e-05	0.000321	CcSEcCtD
Riluzole—Diarrhoea—Gemcitabine—pancreatic cancer	8.53e-05	0.00032	CcSEcCtD
Riluzole—Neuropathy peripheral—Doxorubicin—pancreatic cancer	8.48e-05	0.000318	CcSEcCtD
Riluzole—Dizziness—Irinotecan—pancreatic cancer	8.46e-05	0.000317	CcSEcCtD
Riluzole—Haemoglobin—Epirubicin—pancreatic cancer	8.44e-05	0.000316	CcSEcCtD
Riluzole—Jaundice—Doxorubicin—pancreatic cancer	8.43e-05	0.000316	CcSEcCtD
Riluzole—Stomatitis—Doxorubicin—pancreatic cancer	8.43e-05	0.000316	CcSEcCtD
Riluzole—Anorexia—Docetaxel—pancreatic cancer	8.43e-05	0.000316	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	8.42e-05	0.00318	CbGpPWpGaD
Riluzole—Rhinitis—Epirubicin—pancreatic cancer	8.42e-05	0.000316	CcSEcCtD
Riluzole—Urinary tract infection—Doxorubicin—pancreatic cancer	8.41e-05	0.000315	CcSEcCtD
Riluzole—Haemorrhage—Epirubicin—pancreatic cancer	8.4e-05	0.000315	CcSEcCtD
Riluzole—Hepatitis—Epirubicin—pancreatic cancer	8.4e-05	0.000315	CcSEcCtD
Riluzole—Diarrhoea—Fluorouracil—pancreatic cancer	8.38e-05	0.000314	CcSEcCtD
Riluzole—Hypoaesthesia—Epirubicin—pancreatic cancer	8.35e-05	0.000313	CcSEcCtD
Riluzole—Pharyngitis—Epirubicin—pancreatic cancer	8.33e-05	0.000313	CcSEcCtD
Riluzole—Sweating—Doxorubicin—pancreatic cancer	8.3e-05	0.000311	CcSEcCtD
Riluzole—Urinary tract disorder—Epirubicin—pancreatic cancer	8.29e-05	0.000311	CcSEcCtD
Riluzole—Oedema peripheral—Epirubicin—pancreatic cancer	8.27e-05	0.00031	CcSEcCtD
Riluzole—Hypotension—Docetaxel—pancreatic cancer	8.26e-05	0.00031	CcSEcCtD
Riluzole—Haematuria—Doxorubicin—pancreatic cancer	8.25e-05	0.000309	CcSEcCtD
Riluzole—Connective tissue disorder—Epirubicin—pancreatic cancer	8.25e-05	0.000309	CcSEcCtD
Riluzole—Urethral disorder—Epirubicin—pancreatic cancer	8.23e-05	0.000309	CcSEcCtD
Riluzole—Hepatobiliary disease—Doxorubicin—pancreatic cancer	8.18e-05	0.000307	CcSEcCtD
Riluzole—Epistaxis—Doxorubicin—pancreatic cancer	8.16e-05	0.000306	CcSEcCtD
Riluzole—Vomiting—Irinotecan—pancreatic cancer	8.13e-05	0.000305	CcSEcCtD
Riluzole—Sinusitis—Doxorubicin—pancreatic cancer	8.12e-05	0.000304	CcSEcCtD
Riluzole—Dizziness—Fluorouracil—pancreatic cancer	8.1e-05	0.000304	CcSEcCtD
Riluzole—Agranulocytosis—Doxorubicin—pancreatic cancer	8.07e-05	0.000303	CcSEcCtD
Riluzole—Rash—Irinotecan—pancreatic cancer	8.07e-05	0.000303	CcSEcCtD
Riluzole—Dermatitis—Irinotecan—pancreatic cancer	8.06e-05	0.000302	CcSEcCtD
Riluzole—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	8.06e-05	0.000302	CcSEcCtD
Riluzole—Headache—Irinotecan—pancreatic cancer	8.01e-05	0.000301	CcSEcCtD
Riluzole—SCN5A—L1CAM interactions—EGFR—pancreatic cancer	8.01e-05	0.00303	CbGpPWpGaD
Riluzole—Insomnia—Docetaxel—pancreatic cancer	8e-05	0.0003	CcSEcCtD
Riluzole—Paraesthesia—Docetaxel—pancreatic cancer	7.94e-05	0.000298	CcSEcCtD
Riluzole—Erythema multiforme—Epirubicin—pancreatic cancer	7.94e-05	0.000298	CcSEcCtD
Riluzole—Vomiting—Gemcitabine—pancreatic cancer	7.92e-05	0.000297	CcSEcCtD
Riluzole—Bradycardia—Doxorubicin—pancreatic cancer	7.91e-05	0.000297	CcSEcCtD
Riluzole—Dyspnoea—Docetaxel—pancreatic cancer	7.88e-05	0.000296	CcSEcCtD
Riluzole—CYP1A1—Arachidonic acid metabolism—PTGS2—pancreatic cancer	7.88e-05	0.00298	CbGpPWpGaD
Riluzole—Somnolence—Docetaxel—pancreatic cancer	7.86e-05	0.000295	CcSEcCtD
Riluzole—Rash—Gemcitabine—pancreatic cancer	7.86e-05	0.000295	CcSEcCtD
Riluzole—Dermatitis—Gemcitabine—pancreatic cancer	7.85e-05	0.000294	CcSEcCtD
Riluzole—Eye disorder—Epirubicin—pancreatic cancer	7.85e-05	0.000294	CcSEcCtD
Riluzole—Haemoglobin—Doxorubicin—pancreatic cancer	7.81e-05	0.000293	CcSEcCtD
Riluzole—Headache—Gemcitabine—pancreatic cancer	7.81e-05	0.000293	CcSEcCtD
Riluzole—Cardiac disorder—Epirubicin—pancreatic cancer	7.79e-05	0.000292	CcSEcCtD
Riluzole—Vomiting—Fluorouracil—pancreatic cancer	7.79e-05	0.000292	CcSEcCtD
Riluzole—Rhinitis—Doxorubicin—pancreatic cancer	7.79e-05	0.000292	CcSEcCtD
Riluzole—Dyspepsia—Docetaxel—pancreatic cancer	7.78e-05	0.000292	CcSEcCtD
Riluzole—Haemorrhage—Doxorubicin—pancreatic cancer	7.77e-05	0.000291	CcSEcCtD
Riluzole—Hepatitis—Doxorubicin—pancreatic cancer	7.77e-05	0.000291	CcSEcCtD
Riluzole—Hypoaesthesia—Doxorubicin—pancreatic cancer	7.73e-05	0.00029	CcSEcCtD
Riluzole—Rash—Fluorouracil—pancreatic cancer	7.72e-05	0.00029	CcSEcCtD
Riluzole—Dermatitis—Fluorouracil—pancreatic cancer	7.72e-05	0.000289	CcSEcCtD
Riluzole—Pharyngitis—Doxorubicin—pancreatic cancer	7.71e-05	0.000289	CcSEcCtD
Riluzole—Decreased appetite—Docetaxel—pancreatic cancer	7.69e-05	0.000288	CcSEcCtD
Riluzole—Headache—Fluorouracil—pancreatic cancer	7.68e-05	0.000288	CcSEcCtD
Riluzole—Urinary tract disorder—Doxorubicin—pancreatic cancer	7.67e-05	0.000288	CcSEcCtD
Riluzole—Oedema peripheral—Doxorubicin—pancreatic cancer	7.65e-05	0.000287	CcSEcCtD
Riluzole—Gastrointestinal disorder—Docetaxel—pancreatic cancer	7.63e-05	0.000286	CcSEcCtD
Riluzole—Connective tissue disorder—Doxorubicin—pancreatic cancer	7.63e-05	0.000286	CcSEcCtD
Riluzole—Fatigue—Docetaxel—pancreatic cancer	7.62e-05	0.000286	CcSEcCtD
Riluzole—Angiopathy—Epirubicin—pancreatic cancer	7.62e-05	0.000286	CcSEcCtD
Riluzole—Urethral disorder—Doxorubicin—pancreatic cancer	7.61e-05	0.000286	CcSEcCtD
Riluzole—Nausea—Irinotecan—pancreatic cancer	7.6e-05	0.000285	CcSEcCtD
Riluzole—Immune system disorder—Epirubicin—pancreatic cancer	7.58e-05	0.000284	CcSEcCtD
Riluzole—Mediastinal disorder—Epirubicin—pancreatic cancer	7.57e-05	0.000284	CcSEcCtD
Riluzole—Constipation—Docetaxel—pancreatic cancer	7.56e-05	0.000284	CcSEcCtD
Riluzole—Pain—Docetaxel—pancreatic cancer	7.56e-05	0.000284	CcSEcCtD
Riluzole—Chills—Epirubicin—pancreatic cancer	7.53e-05	0.000283	CcSEcCtD
Riluzole—Arrhythmia—Epirubicin—pancreatic cancer	7.5e-05	0.000281	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PLAU—pancreatic cancer	7.47e-05	0.00282	CbGpPWpGaD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CXCL8—pancreatic cancer	7.43e-05	0.00281	CbGpPWpGaD
Riluzole—Alopecia—Epirubicin—pancreatic cancer	7.42e-05	0.000278	CcSEcCtD
Riluzole—Nausea—Gemcitabine—pancreatic cancer	7.4e-05	0.000278	CcSEcCtD
Riluzole—Mental disorder—Epirubicin—pancreatic cancer	7.35e-05	0.000276	CcSEcCtD
Riluzole—Erythema multiforme—Doxorubicin—pancreatic cancer	7.34e-05	0.000275	CcSEcCtD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—pancreatic cancer	7.34e-05	0.00277	CbGpPWpGaD
Riluzole—Malnutrition—Epirubicin—pancreatic cancer	7.31e-05	0.000274	CcSEcCtD
Riluzole—Feeling abnormal—Docetaxel—pancreatic cancer	7.29e-05	0.000273	CcSEcCtD
Riluzole—Nausea—Fluorouracil—pancreatic cancer	7.28e-05	0.000273	CcSEcCtD
Riluzole—Eye disorder—Doxorubicin—pancreatic cancer	7.26e-05	0.000272	CcSEcCtD
Riluzole—Gastrointestinal pain—Docetaxel—pancreatic cancer	7.23e-05	0.000271	CcSEcCtD
Riluzole—Cardiac disorder—Doxorubicin—pancreatic cancer	7.21e-05	0.00027	CcSEcCtD
Riluzole—Flatulence—Epirubicin—pancreatic cancer	7.2e-05	0.00027	CcSEcCtD
Riluzole—Tension—Epirubicin—pancreatic cancer	7.17e-05	0.000269	CcSEcCtD
Riluzole—Dysgeusia—Epirubicin—pancreatic cancer	7.16e-05	0.000268	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CASP3—pancreatic cancer	7.11e-05	0.00269	CbGpPWpGaD
Riluzole—Nervousness—Epirubicin—pancreatic cancer	7.1e-05	0.000266	CcSEcCtD
Riluzole—Back pain—Epirubicin—pancreatic cancer	7.07e-05	0.000265	CcSEcCtD
Riluzole—Angiopathy—Doxorubicin—pancreatic cancer	7.05e-05	0.000264	CcSEcCtD
Riluzole—Muscle spasms—Epirubicin—pancreatic cancer	7.03e-05	0.000264	CcSEcCtD
Riluzole—Immune system disorder—Doxorubicin—pancreatic cancer	7.02e-05	0.000263	CcSEcCtD
Riluzole—Mediastinal disorder—Doxorubicin—pancreatic cancer	7e-05	0.000263	CcSEcCtD
Riluzole—Abdominal pain—Docetaxel—pancreatic cancer	6.99e-05	0.000262	CcSEcCtD
Riluzole—Body temperature increased—Docetaxel—pancreatic cancer	6.99e-05	0.000262	CcSEcCtD
Riluzole—Chills—Doxorubicin—pancreatic cancer	6.97e-05	0.000261	CcSEcCtD
Riluzole—Arrhythmia—Doxorubicin—pancreatic cancer	6.94e-05	0.00026	CcSEcCtD
Riluzole—Alopecia—Doxorubicin—pancreatic cancer	6.86e-05	0.000257	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—CTNNB1—pancreatic cancer	6.86e-05	0.00259	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	6.81e-05	0.00257	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	6.81e-05	0.00257	CbGpPWpGaD
Riluzole—Mental disorder—Doxorubicin—pancreatic cancer	6.81e-05	0.000255	CcSEcCtD
Riluzole—Ill-defined disorder—Epirubicin—pancreatic cancer	6.78e-05	0.000254	CcSEcCtD
Riluzole—Malnutrition—Doxorubicin—pancreatic cancer	6.76e-05	0.000254	CcSEcCtD
Riluzole—Anaemia—Epirubicin—pancreatic cancer	6.75e-05	0.000253	CcSEcCtD
Riluzole—Agitation—Epirubicin—pancreatic cancer	6.72e-05	0.000252	CcSEcCtD
Riluzole—Flatulence—Doxorubicin—pancreatic cancer	6.66e-05	0.00025	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PIK3CG—pancreatic cancer	6.65e-05	0.00251	CbGpPWpGaD
Riluzole—Tension—Doxorubicin—pancreatic cancer	6.64e-05	0.000249	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	6.64e-05	0.00251	CbGpPWpGaD
Riluzole—Dysgeusia—Doxorubicin—pancreatic cancer	6.62e-05	0.000248	CcSEcCtD
Riluzole—Malaise—Epirubicin—pancreatic cancer	6.59e-05	0.000247	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—EGF—pancreatic cancer	6.57e-05	0.00248	CbGpPWpGaD
Riluzole—Nervousness—Doxorubicin—pancreatic cancer	6.57e-05	0.000246	CcSEcCtD
Riluzole—Vertigo—Epirubicin—pancreatic cancer	6.57e-05	0.000246	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	6.55e-05	0.00248	CbGpPWpGaD
Riluzole—Syncope—Epirubicin—pancreatic cancer	6.55e-05	0.000246	CcSEcCtD
Riluzole—Leukopenia—Epirubicin—pancreatic cancer	6.54e-05	0.000245	CcSEcCtD
Riluzole—Back pain—Doxorubicin—pancreatic cancer	6.54e-05	0.000245	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—RB1—pancreatic cancer	6.53e-05	0.00247	CbGpPWpGaD
Riluzole—Hypersensitivity—Docetaxel—pancreatic cancer	6.51e-05	0.000244	CcSEcCtD
Riluzole—Muscle spasms—Doxorubicin—pancreatic cancer	6.5e-05	0.000244	CcSEcCtD
Riluzole—Palpitations—Epirubicin—pancreatic cancer	6.46e-05	0.000242	CcSEcCtD
Riluzole—Loss of consciousness—Epirubicin—pancreatic cancer	6.42e-05	0.000241	CcSEcCtD
Riluzole—Cough—Epirubicin—pancreatic cancer	6.38e-05	0.000239	CcSEcCtD
Riluzole—Asthenia—Docetaxel—pancreatic cancer	6.34e-05	0.000238	CcSEcCtD
Riluzole—Convulsion—Epirubicin—pancreatic cancer	6.33e-05	0.000237	CcSEcCtD
Riluzole—Hypertension—Epirubicin—pancreatic cancer	6.31e-05	0.000237	CcSEcCtD
Riluzole—Ill-defined disorder—Doxorubicin—pancreatic cancer	6.27e-05	0.000235	CcSEcCtD
Riluzole—Pruritus—Docetaxel—pancreatic cancer	6.26e-05	0.000235	CcSEcCtD
Riluzole—Anaemia—Doxorubicin—pancreatic cancer	6.25e-05	0.000234	CcSEcCtD
Riluzole—Chest pain—Epirubicin—pancreatic cancer	6.22e-05	0.000233	CcSEcCtD
Riluzole—Myalgia—Epirubicin—pancreatic cancer	6.22e-05	0.000233	CcSEcCtD
Riluzole—Arthralgia—Epirubicin—pancreatic cancer	6.22e-05	0.000233	CcSEcCtD
Riluzole—Agitation—Doxorubicin—pancreatic cancer	6.21e-05	0.000233	CcSEcCtD
Riluzole—Anxiety—Epirubicin—pancreatic cancer	6.2e-05	0.000233	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	6.18e-05	0.000232	CcSEcCtD
Riluzole—Discomfort—Epirubicin—pancreatic cancer	6.15e-05	0.000231	CcSEcCtD
Riluzole—SCN5A—Axon guidance—KDR—pancreatic cancer	6.11e-05	0.00231	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	6.1e-05	0.00231	CbGpPWpGaD
Riluzole—Malaise—Doxorubicin—pancreatic cancer	6.1e-05	0.000229	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	6.09e-05	0.0023	CbGpPWpGaD
Riluzole—Dry mouth—Epirubicin—pancreatic cancer	6.08e-05	0.000228	CcSEcCtD
Riluzole—Vertigo—Doxorubicin—pancreatic cancer	6.08e-05	0.000228	CcSEcCtD
Riluzole—Syncope—Doxorubicin—pancreatic cancer	6.06e-05	0.000227	CcSEcCtD
Riluzole—Leukopenia—Doxorubicin—pancreatic cancer	6.05e-05	0.000227	CcSEcCtD
Riluzole—Diarrhoea—Docetaxel—pancreatic cancer	6.05e-05	0.000227	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—VEGFA—pancreatic cancer	6.04e-05	0.00228	CbGpPWpGaD
Riluzole—Confusional state—Epirubicin—pancreatic cancer	6.01e-05	0.000226	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MET—pancreatic cancer	5.98e-05	0.00226	CbGpPWpGaD
Riluzole—Palpitations—Doxorubicin—pancreatic cancer	5.98e-05	0.000224	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	5.97e-05	0.00226	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	5.97e-05	0.00226	CbGpPWpGaD
Riluzole—Anaphylactic shock—Epirubicin—pancreatic cancer	5.96e-05	0.000224	CcSEcCtD
Riluzole—Oedema—Epirubicin—pancreatic cancer	5.96e-05	0.000224	CcSEcCtD
Riluzole—Loss of consciousness—Doxorubicin—pancreatic cancer	5.94e-05	0.000223	CcSEcCtD
Riluzole—Infection—Epirubicin—pancreatic cancer	5.93e-05	0.000222	CcSEcCtD
Riluzole—Cough—Doxorubicin—pancreatic cancer	5.9e-05	0.000221	CcSEcCtD
Riluzole—Shock—Epirubicin—pancreatic cancer	5.87e-05	0.00022	CcSEcCtD
Riluzole—Convulsion—Doxorubicin—pancreatic cancer	5.86e-05	0.00022	CcSEcCtD
Riluzole—Nervous system disorder—Epirubicin—pancreatic cancer	5.85e-05	0.000219	CcSEcCtD
Riluzole—Dizziness—Docetaxel—pancreatic cancer	5.85e-05	0.000219	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PIK3CD—pancreatic cancer	5.84e-05	0.00221	CbGpPWpGaD
Riluzole—Thrombocytopenia—Epirubicin—pancreatic cancer	5.84e-05	0.000219	CcSEcCtD
Riluzole—Hypertension—Doxorubicin—pancreatic cancer	5.84e-05	0.000219	CcSEcCtD
Riluzole—Tachycardia—Epirubicin—pancreatic cancer	5.82e-05	0.000218	CcSEcCtD
Riluzole—Skin disorder—Epirubicin—pancreatic cancer	5.79e-05	0.000217	CcSEcCtD
Riluzole—Hyperhidrosis—Epirubicin—pancreatic cancer	5.77e-05	0.000216	CcSEcCtD
Riluzole—Chest pain—Doxorubicin—pancreatic cancer	5.76e-05	0.000216	CcSEcCtD
Riluzole—Myalgia—Doxorubicin—pancreatic cancer	5.76e-05	0.000216	CcSEcCtD
Riluzole—Arthralgia—Doxorubicin—pancreatic cancer	5.76e-05	0.000216	CcSEcCtD
Riluzole—Anxiety—Doxorubicin—pancreatic cancer	5.74e-05	0.000215	CcSEcCtD
Riluzole—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	5.72e-05	0.000214	CcSEcCtD
Riluzole—Discomfort—Doxorubicin—pancreatic cancer	5.69e-05	0.000213	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	5.69e-05	0.00215	CbGpPWpGaD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	5.69e-05	0.00215	CbGpPWpGaD
Riluzole—Anorexia—Epirubicin—pancreatic cancer	5.69e-05	0.000213	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	5.64e-05	0.00213	CbGpPWpGaD
Riluzole—Dry mouth—Doxorubicin—pancreatic cancer	5.63e-05	0.000211	CcSEcCtD
Riluzole—Vomiting—Docetaxel—pancreatic cancer	5.62e-05	0.000211	CcSEcCtD
Riluzole—Rash—Docetaxel—pancreatic cancer	5.58e-05	0.000209	CcSEcCtD
Riluzole—Hypotension—Epirubicin—pancreatic cancer	5.57e-05	0.000209	CcSEcCtD
Riluzole—Dermatitis—Docetaxel—pancreatic cancer	5.57e-05	0.000209	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—SMAD4—pancreatic cancer	5.57e-05	0.0021	CbGpPWpGaD
Riluzole—Confusional state—Doxorubicin—pancreatic cancer	5.56e-05	0.000209	CcSEcCtD
Riluzole—Headache—Docetaxel—pancreatic cancer	5.54e-05	0.000208	CcSEcCtD
Riluzole—Oedema—Doxorubicin—pancreatic cancer	5.52e-05	0.000207	CcSEcCtD
Riluzole—Anaphylactic shock—Doxorubicin—pancreatic cancer	5.52e-05	0.000207	CcSEcCtD
Riluzole—Infection—Doxorubicin—pancreatic cancer	5.48e-05	0.000206	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—HES1—pancreatic cancer	5.44e-05	0.00205	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	5.43e-05	0.000204	CcSEcCtD
Riluzole—Shock—Doxorubicin—pancreatic cancer	5.43e-05	0.000204	CcSEcCtD
Riluzole—Nervous system disorder—Doxorubicin—pancreatic cancer	5.41e-05	0.000203	CcSEcCtD
Riluzole—Thrombocytopenia—Doxorubicin—pancreatic cancer	5.4e-05	0.000203	CcSEcCtD
Riluzole—Insomnia—Epirubicin—pancreatic cancer	5.39e-05	0.000202	CcSEcCtD
Riluzole—Tachycardia—Doxorubicin—pancreatic cancer	5.39e-05	0.000202	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—pancreatic cancer	5.37e-05	0.00203	CbGpPWpGaD
Riluzole—Skin disorder—Doxorubicin—pancreatic cancer	5.36e-05	0.000201	CcSEcCtD
Riluzole—Paraesthesia—Epirubicin—pancreatic cancer	5.36e-05	0.000201	CcSEcCtD
Riluzole—Hyperhidrosis—Doxorubicin—pancreatic cancer	5.34e-05	0.0002	CcSEcCtD
Riluzole—CYP1A1—PPARA activates gene expression—PPARG—pancreatic cancer	5.33e-05	0.00201	CbGpPWpGaD
Riluzole—Dyspnoea—Epirubicin—pancreatic cancer	5.32e-05	0.000199	CcSEcCtD
Riluzole—Somnolence—Epirubicin—pancreatic cancer	5.3e-05	0.000199	CcSEcCtD
Riluzole—Anorexia—Doxorubicin—pancreatic cancer	5.26e-05	0.000197	CcSEcCtD
Riluzole—Nausea—Docetaxel—pancreatic cancer	5.25e-05	0.000197	CcSEcCtD
Riluzole—Dyspepsia—Epirubicin—pancreatic cancer	5.25e-05	0.000197	CcSEcCtD
Riluzole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—pancreatic cancer	5.22e-05	0.00197	CbGpPWpGaD
Riluzole—Decreased appetite—Epirubicin—pancreatic cancer	5.18e-05	0.000194	CcSEcCtD
Riluzole—SCN5A—SIDS Susceptibility Pathways—TNF—pancreatic cancer	5.17e-05	0.00196	CbGpPWpGaD
Riluzole—Hypotension—Doxorubicin—pancreatic cancer	5.16e-05	0.000193	CcSEcCtD
Riluzole—Gastrointestinal disorder—Epirubicin—pancreatic cancer	5.15e-05	0.000193	CcSEcCtD
Riluzole—Fatigue—Epirubicin—pancreatic cancer	5.14e-05	0.000193	CcSEcCtD
Riluzole—Pain—Epirubicin—pancreatic cancer	5.1e-05	0.000191	CcSEcCtD
Riluzole—Constipation—Epirubicin—pancreatic cancer	5.1e-05	0.000191	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PIK3CB—pancreatic cancer	5.09e-05	0.00192	CbGpPWpGaD
Riluzole—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	5.03e-05	0.000189	CcSEcCtD
Riluzole—CYP1A2—Arachidonic acid metabolism—PTGS2—pancreatic cancer	5.02e-05	0.0019	CbGpPWpGaD
Riluzole—Insomnia—Doxorubicin—pancreatic cancer	4.99e-05	0.000187	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MMP2—pancreatic cancer	4.98e-05	0.00188	CbGpPWpGaD
Riluzole—Paraesthesia—Doxorubicin—pancreatic cancer	4.96e-05	0.000186	CcSEcCtD
Riluzole—Dyspnoea—Doxorubicin—pancreatic cancer	4.92e-05	0.000185	CcSEcCtD
Riluzole—Feeling abnormal—Epirubicin—pancreatic cancer	4.92e-05	0.000184	CcSEcCtD
Riluzole—Somnolence—Doxorubicin—pancreatic cancer	4.91e-05	0.000184	CcSEcCtD
Riluzole—Gastrointestinal pain—Epirubicin—pancreatic cancer	4.88e-05	0.000183	CcSEcCtD
Riluzole—Dyspepsia—Doxorubicin—pancreatic cancer	4.86e-05	0.000182	CcSEcCtD
Riluzole—Decreased appetite—Doxorubicin—pancreatic cancer	4.8e-05	0.00018	CcSEcCtD
Riluzole—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	4.79e-05	0.00181	CbGpPWpGaD
Riluzole—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	4.76e-05	0.000179	CcSEcCtD
Riluzole—Fatigue—Doxorubicin—pancreatic cancer	4.76e-05	0.000178	CcSEcCtD
Riluzole—Urticaria—Epirubicin—pancreatic cancer	4.74e-05	0.000178	CcSEcCtD
Riluzole—ABCG2—Transmembrane transport of small molecules—SLC2A2—pancreatic cancer	4.73e-05	0.00179	CbGpPWpGaD
Riluzole—Pain—Doxorubicin—pancreatic cancer	4.72e-05	0.000177	CcSEcCtD
Riluzole—Constipation—Doxorubicin—pancreatic cancer	4.72e-05	0.000177	CcSEcCtD
Riluzole—Abdominal pain—Epirubicin—pancreatic cancer	4.71e-05	0.000177	CcSEcCtD
Riluzole—Body temperature increased—Epirubicin—pancreatic cancer	4.71e-05	0.000177	CcSEcCtD
Riluzole—ABCG2—HIF-1-alpha transcription factor network—AKT1—pancreatic cancer	4.69e-05	0.00177	CbGpPWpGaD
Riluzole—Feeling abnormal—Doxorubicin—pancreatic cancer	4.55e-05	0.000171	CcSEcCtD
Riluzole—Gastrointestinal pain—Doxorubicin—pancreatic cancer	4.51e-05	0.000169	CcSEcCtD
Riluzole—Hypersensitivity—Epirubicin—pancreatic cancer	4.39e-05	0.000165	CcSEcCtD
Riluzole—Urticaria—Doxorubicin—pancreatic cancer	4.38e-05	0.000164	CcSEcCtD
Riluzole—Body temperature increased—Doxorubicin—pancreatic cancer	4.36e-05	0.000164	CcSEcCtD
Riluzole—Abdominal pain—Doxorubicin—pancreatic cancer	4.36e-05	0.000164	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—KDR—pancreatic cancer	4.36e-05	0.00165	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	4.34e-05	0.00164	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—SRC—pancreatic cancer	4.34e-05	0.00164	CbGpPWpGaD
Riluzole—Asthenia—Epirubicin—pancreatic cancer	4.28e-05	0.00016	CcSEcCtD
Riluzole—SCN5A—Developmental Biology—MET—pancreatic cancer	4.26e-05	0.00161	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—pancreatic cancer	4.23e-05	0.0016	CbGpPWpGaD
Riluzole—Pruritus—Epirubicin—pancreatic cancer	4.22e-05	0.000158	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—pancreatic cancer	4.18e-05	0.00158	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NOTCH1—pancreatic cancer	4.1e-05	0.00155	CbGpPWpGaD
Riluzole—Diarrhoea—Epirubicin—pancreatic cancer	4.08e-05	0.000153	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—SRC—pancreatic cancer	4.08e-05	0.00154	CbGpPWpGaD
Riluzole—Hypersensitivity—Doxorubicin—pancreatic cancer	4.07e-05	0.000152	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—VEGFA—pancreatic cancer	3.97e-05	0.0015	CbGpPWpGaD
Riluzole—Asthenia—Doxorubicin—pancreatic cancer	3.96e-05	0.000149	CcSEcCtD
Riluzole—Dizziness—Epirubicin—pancreatic cancer	3.94e-05	0.000148	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—NRAS—pancreatic cancer	3.93e-05	0.00148	CbGpPWpGaD
Riluzole—Pruritus—Doxorubicin—pancreatic cancer	3.9e-05	0.000146	CcSEcCtD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—MYC—pancreatic cancer	3.89e-05	0.00147	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	3.88e-05	0.00147	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PRSS1—pancreatic cancer	3.88e-05	0.00147	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—PPARG—pancreatic cancer	3.87e-05	0.00146	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—pancreatic cancer	3.81e-05	0.00144	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	3.81e-05	0.00144	CbGpPWpGaD
Riluzole—Vomiting—Epirubicin—pancreatic cancer	3.79e-05	0.000142	CcSEcCtD
Riluzole—Diarrhoea—Doxorubicin—pancreatic cancer	3.78e-05	0.000142	CcSEcCtD
Riluzole—Rash—Epirubicin—pancreatic cancer	3.76e-05	0.000141	CcSEcCtD
Riluzole—Dermatitis—Epirubicin—pancreatic cancer	3.76e-05	0.000141	CcSEcCtD
Riluzole—SCN5A—Axon guidance—MMP9—pancreatic cancer	3.75e-05	0.00142	CbGpPWpGaD
Riluzole—Headache—Epirubicin—pancreatic cancer	3.74e-05	0.00014	CcSEcCtD
Riluzole—Dizziness—Doxorubicin—pancreatic cancer	3.65e-05	0.000137	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—TGFB1—pancreatic cancer	3.65e-05	0.00138	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	3.63e-05	0.00137	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—pancreatic cancer	3.63e-05	0.00137	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—pancreatic cancer	3.6e-05	0.00136	CbGpPWpGaD
Riluzole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—pancreatic cancer	3.59e-05	0.00136	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MMP2—pancreatic cancer	3.56e-05	0.00134	CbGpPWpGaD
Riluzole—Nausea—Epirubicin—pancreatic cancer	3.54e-05	0.000133	CcSEcCtD
Riluzole—Vomiting—Doxorubicin—pancreatic cancer	3.51e-05	0.000132	CcSEcCtD
Riluzole—Rash—Doxorubicin—pancreatic cancer	3.48e-05	0.000131	CcSEcCtD
Riluzole—Dermatitis—Doxorubicin—pancreatic cancer	3.48e-05	0.00013	CcSEcCtD
Riluzole—Headache—Doxorubicin—pancreatic cancer	3.46e-05	0.00013	CcSEcCtD
Riluzole—SCN5A—Axon guidance—SRC—pancreatic cancer	3.45e-05	0.00131	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—KRAS—pancreatic cancer	3.38e-05	0.00128	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—ARG2—pancreatic cancer	3.37e-05	0.00127	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—VEGFA—pancreatic cancer	3.36e-05	0.00127	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—NRAS—pancreatic cancer	3.32e-05	0.00126	CbGpPWpGaD
Riluzole—Nausea—Doxorubicin—pancreatic cancer	3.28e-05	0.000123	CcSEcCtD
Riluzole—SLC7A11—Hemostasis—PIK3CA—pancreatic cancer	3.1e-05	0.00117	CbGpPWpGaD
Riluzole—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—pancreatic cancer	3.06e-05	0.00116	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—EGFR—pancreatic cancer	3.03e-05	0.00114	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—TP53—pancreatic cancer	3e-05	0.00113	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TYMP—pancreatic cancer	2.94e-05	0.00111	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—HRAS—pancreatic cancer	2.87e-05	0.00109	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—KRAS—pancreatic cancer	2.86e-05	0.00108	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—CTNNB1—pancreatic cancer	2.73e-05	0.00103	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—MMP9—pancreatic cancer	2.67e-05	0.00101	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PRSS1—pancreatic cancer	2.63e-05	0.000993	CbGpPWpGaD
Riluzole—SLC7A11—Hemostasis—AKT1—pancreatic cancer	2.54e-05	0.000958	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—SRC—pancreatic cancer	2.46e-05	0.000931	CbGpPWpGaD
Riluzole—SCN5A—Axon guidance—HRAS—pancreatic cancer	2.43e-05	0.000919	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—VEGFA—pancreatic cancer	2.4e-05	0.000907	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—STAT3—pancreatic cancer	2.38e-05	0.000898	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GLP1R—pancreatic cancer	2.37e-05	0.000896	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—NRAS—pancreatic cancer	2.37e-05	0.000896	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—DPYD—pancreatic cancer	2.33e-05	0.000882	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—ARG2—pancreatic cancer	2.28e-05	0.000861	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—SLC2A2—pancreatic cancer	2.21e-05	0.000837	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TGFB1—pancreatic cancer	2.2e-05	0.000833	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—EGFR—pancreatic cancer	2.16e-05	0.000816	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—TNF—pancreatic cancer	2.06e-05	0.000777	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—KRAS—pancreatic cancer	2.04e-05	0.000771	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMP—pancreatic cancer	1.99e-05	0.000753	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—HRAS—pancreatic cancer	1.73e-05	0.000656	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—CD44—pancreatic cancer	1.71e-05	0.000648	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PRSS1—pancreatic cancer	1.68e-05	0.000633	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—GCG—pancreatic cancer	1.64e-05	0.000621	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.64e-05	0.000621	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GLP1R—pancreatic cancer	1.61e-05	0.000607	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—DPYD—pancreatic cancer	1.58e-05	0.000597	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—STK11—pancreatic cancer	1.55e-05	0.000584	CbGpPWpGaD
Riluzole—SCN5A—Developmental Biology—AKT1—pancreatic cancer	1.53e-05	0.000579	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—SLC2A2—pancreatic cancer	1.5e-05	0.000566	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.48e-05	0.000561	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—ARG2—pancreatic cancer	1.45e-05	0.000549	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.43e-05	0.000541	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—TYMS—pancreatic cancer	1.33e-05	0.000502	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.3e-05	0.000493	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMP—pancreatic cancer	1.27e-05	0.00048	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—CD44—pancreatic cancer	1.16e-05	0.000439	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.14e-05	0.000429	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.13e-05	0.000426	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—GCG—pancreatic cancer	1.11e-05	0.000421	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—APOE—pancreatic cancer	1.08e-05	0.000409	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.05e-05	0.000396	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—STK11—pancreatic cancer	1.05e-05	0.000395	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GLP1R—pancreatic cancer	1.02e-05	0.000387	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—DPYD—pancreatic cancer	1.01e-05	0.000381	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	9.82e-06	0.000371	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CG—pancreatic cancer	9.76e-06	0.000369	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—SLC2A2—pancreatic cancer	9.56e-06	0.000361	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	9.46e-06	0.000357	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PPARG—pancreatic cancer	9.42e-06	0.000356	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	9.13e-06	0.000345	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—TYMS—pancreatic cancer	9e-06	0.00034	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CD—pancreatic cancer	8.58e-06	0.000324	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	8.31e-06	0.000314	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CB—pancreatic cancer	7.48e-06	0.000283	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTGS2—pancreatic cancer	7.41e-06	0.00028	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—CD44—pancreatic cancer	7.4e-06	0.00028	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—APOE—pancreatic cancer	7.32e-06	0.000277	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	7.25e-06	0.000274	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	7.18e-06	0.000271	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—GCG—pancreatic cancer	7.1e-06	0.000268	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.93e-06	0.000262	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—STK11—pancreatic cancer	6.67e-06	0.000252	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CG—pancreatic cancer	6.61e-06	0.00025	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PTEN—pancreatic cancer	6.46e-06	0.000244	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PPARG—pancreatic cancer	6.38e-06	0.000241	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	6.26e-06	0.000237	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CD—pancreatic cancer	5.81e-06	0.000219	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—TYMS—pancreatic cancer	5.74e-06	0.000217	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CB—pancreatic cancer	5.06e-06	0.000191	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTGS2—pancreatic cancer	5.02e-06	0.00019	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—APOE—pancreatic cancer	4.67e-06	0.000176	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—PIK3CA—pancreatic cancer	4.56e-06	0.000172	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	4.42e-06	0.000167	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PTEN—pancreatic cancer	4.37e-06	0.000165	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CG—pancreatic cancer	4.21e-06	0.000159	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PPARG—pancreatic cancer	4.07e-06	0.000154	CbGpPWpGaD
Riluzole—ABCG2—Metabolism—AKT1—pancreatic cancer	3.72e-06	0.000141	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CD—pancreatic cancer	3.7e-06	0.00014	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CB—pancreatic cancer	3.23e-06	0.000122	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTGS2—pancreatic cancer	3.2e-06	0.000121	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—PIK3CA—pancreatic cancer	3.09e-06	0.000117	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PTEN—pancreatic cancer	2.79e-06	0.000105	CbGpPWpGaD
Riluzole—CYP1A1—Metabolism—AKT1—pancreatic cancer	2.52e-06	9.53e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—PIK3CA—pancreatic cancer	1.97e-06	7.43e-05	CbGpPWpGaD
Riluzole—CYP1A2—Metabolism—AKT1—pancreatic cancer	1.61e-06	6.07e-05	CbGpPWpGaD
